Beam Therapeutics Inc. Common Stock (BEAM)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for demonstrated earning power, durable competitive advantages, and a margin of safety. Beam Therapeutics offers none of these today in reported numbers. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $490,000 and net loss was $122.7M, or diluted EPS -$1.18. In fiscal year 2025, the year ended 2025-12-31, revenue was $139.7M and net loss was $80.0M, or diluted EPS -$0.81. That loss was narrower than fiscal year 2024's net loss of $376.7M, but revenue fell from fiscal year 2023's $377.7M to fiscal year 2025's $139.7M, showing no steady commercial ramp. TTM free cash flow was -$372.8M, with an FCF yield of -14.8%, so cash burn is real. The balance sheet has low leverage, with a D/E of 0.23 and an Altman Z-Score of 3.52 by FairStock's calculation, but a Piotroski F-Score of 1/9 signals weak fundamentals. At the 2026-10-13 close of $24.43, the market cap is $2.5B, P/B is 2.29, and P/E is negative. For a company with $490,000 of quarterly revenue and no profits, the price rests on pipeline hopes, not current earnings. In biotech, the moat is intellectual property, clinical data, regulatory approvals, and manufacturing. Those are not yet demonstrated in the figures. The company has programs like Ristoglogene autogetemcel, BEAM-302, and BEAM-304, but the financials show losses every year and no Lynch category because of four straight loss years. I would call this speculative, not a value investment, until revenue and cash flow improve.

In plain English: Beam Therapeutics is a biotechnology company working on precision genetic medicines for serious diseases. It is not yet profitable, its latest quarter had very little revenue, and it is spending heavily, so the business looks financially weak today. At $24.43, the stock looks expensive relative to its current sales and losses, with much depending on future products that have not yet been proven.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer